FDA Panel Rejects MDMA for PTSD Treatment
TL;DR Summary
An FDA advisory panel has rejected the use of MDMA-assisted therapy for treating PTSD, citing concerns over study design, potential bias, cardiovascular risks, and the possibility of drug abuse. The panel's decision was influenced by issues such as participants' ability to guess if they received MDMA and a case of misconduct during the trials.
- FDA Panel Rejects Use of MDMA for Treatment of PTSD The New York Times
- FDA advisors reject MDMA as treatment for PTSD : Shots - Health News NPR
- MDMA therapy wait goes on as FDA panel rejects Lykos' PTSD treatment Yahoo Finance
- The psychedelic medicine revolution just took a big loss POLITICO
- Psychedelics Are Challenging the Scientific Gold Standard The Atlantic
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 2 min read
Condensed
86%
378 → 54 words
Want the full story? Read the original article
Read on The New York Times